5-10% of those taking GLP-1 agonists discontinue treatment citing nausea, diarrhea, indigestion, vomiting, and abdominal pain. Patients often must change not j

5-10% of those taking GLP-1 agonists discontinue treatment citing nausea, diarrhea, indigestion, vomiting, and abdominal pain. Patients often must change not just how much they eat but what they eat, especially, reducing fat intake, eating smaller meals, and staying active right after eating. "What are the gastrointestinal adverse effects of the glucagon-like peptide 1 receptor agonists, and how should they be managed?" https://illinoisadvance.com/what-are-gastrointestinal-adverse-effects-glucagon-peptide-1-receptor-agonists-and-how-should-they-be-managed/ https://illinoisadvance.com/what-are-gastrointestinal-advers... "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss" https://jamanetwork.com/journals/jama/fullarticle/2810542 https://jamanetwork.com/journals/jama/fullarticle/2810542